Efficacy and safety of bivalirudin without post-procedure infusion in patients with coronary heart disease during elective percutaneous coronary intervention : a real-world study
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:135 |
|---|---|
| Enthalten in: |
Chinese medical journal - 135(2022), 1 vom: 05. Jan., Seite 116-118 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Ping [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9005-49-6 |
|---|
| Anmerkungen: |
Date Completed 02.02.2022 Date Revised 30.03.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/CM9.0000000000001757 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331776332 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331776332 | ||
| 003 | DE-627 | ||
| 005 | 20231225214215.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/CM9.0000000000001757 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1105.xml |
| 035 | |a (DE-627)NLM331776332 | ||
| 035 | |a (NLM)34636772 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Ping |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of bivalirudin without post-procedure infusion in patients with coronary heart disease during elective percutaneous coronary intervention |b a real-world study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.02.2022 | ||
| 500 | |a Date Revised 30.03.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Antithrombins |2 NLM | |
| 650 | 7 | |a Hirudins |2 NLM | |
| 650 | 7 | |a Peptide Fragments |2 NLM | |
| 650 | 7 | |a Recombinant Proteins |2 NLM | |
| 650 | 7 | |a Heparin |2 NLM | |
| 650 | 7 | |a 9005-49-6 |2 NLM | |
| 650 | 7 | |a bivalirudin |2 NLM | |
| 650 | 7 | |a TN9BEX005G |2 NLM | |
| 700 | 1 | |a Zhao, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Qimin |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Xiaoxue |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xiaozeng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Chinese medical journal |d 1979 |g 135(2022), 1 vom: 05. Jan., Seite 116-118 |w (DE-627)NLM000002755 |x 2542-5641 |7 nnns |
| 773 | 1 | 8 | |g volume:135 |g year:2022 |g number:1 |g day:05 |g month:01 |g pages:116-118 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/CM9.0000000000001757 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 135 |j 2022 |e 1 |b 05 |c 01 |h 116-118 | ||